Eric L. Keller - 22 Oct 2026 Form 4 Insider Report for Retension Pharmaceuticals, Inc. (RTSN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
22 Oct 2026, 19:34:01 UTC
Prior SEC filing
13 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Alex Schwartz, Attorney-in-fact
Filing notes and source

Key filing fact

Eric L. Keller filed Form 4 for Retension Pharmaceuticals, Inc. (RTSN) on 22 Oct 2026.

Key facts

  • This page summarizes Eric L. Keller's Form 4 filing for Retension Pharmaceuticals, Inc. (RTSN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 22 Oct 2026, 19:34.

Change

  • Previous filing in this sequence was filed on 13 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002156365 Primary reporting owner

Keller Eric L.

Relationship
CHIEF EXECUTIVE OFFICER, Director
Address
1104 WEST BROAD STREET, SUITE 1029, FALLS CHURCH
Signature
/s/ Alex Schwartz, Attorney-in-fact
Signature date
22 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RTSN transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+40,884
Change %
Price
$0.000000*
Shares after
40,884
Date
22 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
40,884
Exercise price
$15.50
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. The option award was granted as a result of the underwriters' exercise of their over-allotment option on October 22, 2026 in connection with the Issuer's initial public offering, pursuant to the terms of the Reporting Person's Offer of Employment Letter with the Issuer, dated August 14, 2026. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .